Among the 390 million annual infections estimated around the world, 240 million are inapparent and only 96 million are symptomatic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: The authors have declared that no competing interests exist.ĭengue fever (DEN) is the most common arboviral disease in the world and is caused by four genetically distinct serotypes of virus (DENV-1, DENV-2, DENV-3, DENV-4) belonging to the genus Flavivirus of the family Flaviviridae. The work is made available under the Creative Commons CC0 public domain dedication.ĭata Availability: All relevant data are within the paper and its Supporting Information files.įunding: This work was funded by National Institute of Health grants R24AI120942 and R01AI121452 and the Institut Pasteur de Dakar.
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. Received: Accepted: DecemPublished: February 13, 2019 PLoS Negl Trop Dis 13(2):Įditor: Rhoel Ramos Dinglasan, University of Florida, UNITED STATES (2019) Potential for sylvatic and urban Aedes mosquitoes from Senegal to transmit the new emerging dengue serotypes 1, 3 and 4 in West Africa. Finally both domestic and wild Senegalese mosquitoes showed a low ability to transmit dengue viruses.Ĭitation: Gaye A, Wang E, Vasilakis N, Guzman H, Diallo D, Talla C, et al. To fill out this gap we experimentally infected domestic and wild mosquitoes from Senegal to assess their vector competence for dengue serotypes 1, 3 and 4. However, the design and the implementation of efficient vector control require an accurate knowledge of the vector bionomics and competence while such data are lacking in the African region. These changes are occurring in a context where vector control remains the only effective approach to prevent and control epidemics.
Serotype 3, never reported in West Africa, caused major outbreaks in 2009 in several capital cities while serotype 2, usually confined to the forest cycle, spilled over into urban areas in Senegal and Mauritania in 2014–2015. In Africa, while dengue outbreaks were rare during the last century, recurrent urban epidemic have been reported in all regions the last decade. luteocephalus.ĭengue fever remains a major public health problem in all tropical regions of the world and causes 390 million infections each year. aegypti populations tested, and 84.6% for the sylvatic vectors Ae. The highest potential transmission rate was 20% despite the high susceptibility and disseminated infection rates up to 93.7% for the 3 Ae. Our results revealed a low capacity of sylvatic and urban Aedes mosquitoes from Senegal to transmit DENV-1, DENV-3 and DENV-4 and an impact of infection on their mortality. Whole bodies and wings/legs were tested for DENV presence by cell culture assays and saliva samples were tested by real time RT-PCR to estimate infection, disseminated infection and transmission rates. (Stegomyia) aegypti populations from Senegal for DENV-1, DENV-3 and DENV-4 using experimental oral infection. (Stegomyia) luteocephalus, sylvatic and urban Ae. We assessed the vector competence of Aedes (Diceromyia) furcifer, Ae. Except for DENV-2, few studies have been performed with serotypes 1, 3, and 4, so this study was undertaken to fill out this gap. Further there is significant gap of knowledge on the vector bionomics and transmission dynamics in the African region to effectively prevent and control epidemics. These important changes in the epidemiological profile of DEN are occurring in a context where there is no qualified vaccine against DEN. In Senegal, all DENV serotypes have been reported. During the past decade a changing epidemiological pattern has been observed in Africa, with DEN outbreaks reported in all regions. Dengue fever (DEN) is the most common arboviral disease in the world and dengue virus (DENV) causes 390 million annual infections around the world, of which 240 million are inapparent and 96 million are symptomatic.